In this five-part series we will bring together expertise from across the firm to cover developments that span the complete lifecycle of this industry’s complex business model—from financing and procurement to regulation and litigation.

COVID-19 may have disrupted IP litigation in 2020, but the year has still seen high-impact developments affecting life sciences companies. Our IP regulatory and litigation team Andy Shaughnessy, Eileen McMahon, Karen Townsend and Alexandra Peterson will review the latest developments—including data protection, patent term extension and strategies, as well as important decisions on substantive patent law—all of which may affect life sciences innovation and business models going forward.

9:00 a.m. EDT Webinar opens
9:15 - 10:15 a.m. EDT Presentation

Ontario: This program is eligible for up to 1.0 Substantive hour.
New York: This program contains 1.0 Areas of Professional Practice Credit.

Click here to register.

Sessions in this series:
Session 1: Navigating (and challenging) a changing life sciences regulatory environment
Session 2: Life sciences product liability litigation: managing risks and anticipating trends
Session 3: The latest developments in life sciences IP litigation
Session 4: Life sciences and centralized procurement: navigating the process and responding to RFPs
Session 5: Financing life sciences on both sides of the border